Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.55 |
| ▸ | PDE4A | P27815 | 10/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904302 | 0.89 | PDE4D (0.55) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL1409231 | 0.85 | ALOX15 (0.53) | PDE4DPDE4BPDE4APDE4CEPHX2 | |
| SCHEMBL5309884 | 0.84 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL7364684 | 0.84 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL7355374 | 0.84 | CA12 (0.54) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL1409590 | 0.84 | PDE4D (0.53) | PDE4DPDE4BPDE4APDE4CEPHX2 | |
| SCHEMBL28650035 | 0.83 | PDE4B (0.50) | PDE4DPDE4BPDE4APDE4CEPHX2 | |
| SCHEMBL7360312 | 0.82 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL27372082 | 0.82 | PDE4D (0.52) | PDE4DPDE4BPDE4APDE4CEPHX2 | |
| SCHEMBL7358414 | 0.81 | PDE4D (0.55) | PDE4DPDE4BPDE4APDE4CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | GOETHE-UNIVERSITY FRANKFURT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | GOETHE-UNIVERSITY FRANKFURT (DE) | 2021-12-23 | — | — | US | disclosed |
| WO-2019079609-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079609-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | EPHX1, PDE4A, EPHX2 | PDE4D 14/4885PDE4B 5/4885PDE4A 2/4885 |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | EPHX1, PDE4A, EPHX2 | PDE4D 14/4885PDE4B 5/4885PDE4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.